期刊文献+

继发于肺动脉高压的慢性右心衰竭与继发于左心疾病的慢性全心衰竭患者通气功能的差异 被引量:4

Differences of Ventilation Function in Patients Between Chronic Right Heart Failure Secondary to Pulmonary Arterial Hypertension and Chronic Whole Heart Failure Secondary to Left Heart Diseases
下载PDF
导出
摘要 目的:探讨慢性右心衰竭(右心衰)与慢性全心衰竭(全心衰)的通气功能的差异。方法:102例临床稳定的慢性心力衰竭(心衰)患者入选该研究,根据心衰情况分为全心衰者(41例),右心衰者(61例)。所有患者均测定静息状态下通气功能,心肺运动试验(CPX)测定运动状态下通气功能。结果:静息状态下,全心衰者及右心衰者通气功能无差异。运动状态下,右心衰者峰值分钟通气量(peak VE)明显低于全心衰者(P<0.05),而无氧阈及峰值分钟通气量与二氧化碳(CO2)生成量比值(VE/VCO2),峰值死腔通气量与潮气量比值(peak VD/VT)高于全心衰者(P<0.05),差异均有统计学意义。结论:静息状态,全心衰者与右心衰者通气功能无差异。运动状态下,右心衰者通气功能及通气效率降低,其原因在于严重的通气血流比(V/Q)异常。 Objective: To study the differences of ventilation function in patients between chronic right heart failure secondary to pulmonary arterial hypertension and chronic whole heart failure secondary to left heart diseases.Methods: A total of 102 patients with clinical stable chronic heart failure(CHF) were studied. The patients were divided into 2 groups: Whole heart failure(WHF) group, n=41 and Right heart failure(RHF) group, n=61. The ventilation function test at rest and cardiopulmonary exercise test(CPX) were conducted and compared between 2 groups.Results: The rest ventilation function was similar between 2 groups. For CPX examination, compared with WHF group, RHF group had the lower peak minute ventilation(VE), higher anaerobic threshold and peak minute ventilation/CO2 production(VE/VCO2), higher peak dead space volume/tidal volume(VD/VT), all P0.05.
出处 《中国循环杂志》 CSCD 北大核心 2014年第12期996-999,共4页 Chinese Circulation Journal
关键词 慢性心力衰竭 通气功能 心肺运动试验 肺动脉高压 Chronic Heart Failure Ventilation Function Cardiopulmonary Exercise Test Pulmonary Arterial Hypertension
  • 相关文献

参考文献2

二级参考文献14

  • 1Mudge GH,Goldstein S,Addonizio LJ,et al.Task force 3:Recipient guidelines/prioritization.J Am Coll Cardiol,1993,22(1):21-26.
  • 2Balady GJ,Arena R,Sietsema K,et al.American Heart Association Exercise,Cardiac Rehabilitation,and Prevention Committee of the Council on Clinical Cardiology;Council on Epidemiology and Prevention;Council on Peripheral Vascular Disease;Interdisciplinary Council on Quality of Care and Outcomes Research.Clinician′s Guide to cardiopulmonary exercise testing in adults:a scientific statement from the American Heart Association.Circulation,2010,122(2):191-225.
  • 3Myers J,Gullestad L,Vagelos R,et al.Cardiopulmonary exercise testing and prognosis in severe heart failure:14 ml/Kg/min revisited.Am Heart J,2000,139(1):78-84.
  • 4Arena R,Myers J,Aslam SS,et al.Peak VO2 and VE/VCO2 slope in patients with heart failure:a prognostic comparison.Am Heart J,2004,147(2):354-360.
  • 5Smith RF,Johnson G,Ziesche S,et al.Functional capacity in heart failure:comparison of methods for assessment and their relation to other indexes of heart failure:the V-He FT VA Cooperative Studies Group.Circulation,1993,87(6 Suppl):V188-V193.
  • 6Gitt AK,Wasserman K,Kilkowski C.Exercise anaerobic threshold and ventilator efficiency identify heart failure patients for high risk of early death.Circulation,2002,106(24):3079-3084.
  • 7Piepoli M,Scott AS,Capucci A,et al.Skeletal muscle training in chronic heart failure.Acta Physiol Scand,2001,171(3):295-303.
  • 8Francis DP,Shamin W,Davies LC,et al.Cardiopulmonary exercise testing for prognosis in chronic heart failure:continuous and independent prognostic value from VE/VCO2 slope and peak VO2.Eur Heart J,2002,21(2):154-161.
  • 9Piepoli M,Ponikowski P,Clark AL,et al.A neural link to explain the ‘muscle hypothesis' of exercise intolerance in chronic heart failure.Am Heart J,1999,137(6):1050-1056.
  • 10无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3700

共引文献15

同被引文献37

  • 1吴学思.心力衰竭的进展(17)B型利钠肽在心力衰竭诊断和治疗中的应用(续12)[J].中国循环杂志,2007,22(5):323-325. 被引量:13
  • 2de Jesus Perez VA. Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Fail Rev, 2015, 21: 239-257.
  • 3Wang RC, Jiang FM, Zheng QL, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med, 2014, 108: 531-537.
  • 4Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med, 2005, 353: 2148- 2157.
  • 5Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation, 2012, 126: 349-356.
  • 6Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol, 2012, 60:1192-1201.
  • 7Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: Importance of cardiopulmonary exercise testing. Circulation, 2002, 106:319-324.
  • 8Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respiratory J, 2004, 24: 1007-1010.
  • 9Oudiz R J, Roveran G, Hansen JE, et al. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail, 2007, 9: 917-921.
  • 10Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers), endorsed by the international society of heart and lung transplantation (ishh). Eur Heart J, 2009, 30: 2493-2537.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部